News

Vyvgart may be safer, more effective than IVIG in older patients

Vyvgart (efgartigimod alfa-fcab) may be safer and more effective than intravenous immunoglobulin (IVIG) therapy in elderly people with generalized myasthenia gravis (gMG), a study shows. In elderly Chinese patients with gMG who were positive for antibodies targeting the acetylcholine receptor (AChR), Vyvgart eased symptoms after four and…

Enrollment opens in Phase 1 trial of NKX019 cell therapy in gMG

Enrollment is open in an investigator-initiated clinical trial to evaluate cell therapy NKX019 in people with myasthenia gravis (MG). Nkarta, the therapy’s developer, made the announcement in a company press release. Researchers at the University of California, Irvine, and the University of Kansas Medical Center are leading the…

Robotic thymectomy safe, effective for treating MG: Study

Robotic thymectomy is a safe and effective treatment for people with myasthenia gravis (MG), including patient groups that have historically showed poorer outcomes, a study found. Five years after undergoing robotic thymectomy, a minimally invasive surgery to remove the thymus gland, 84% of patients saw their MG…

2 new home treatment methods for Rystiggo approved in Japan

Japan’s drug regulatory agency has authorized two new administration methods for Rystiggo (rozanolixizumab) — an approved treatment for generalized myasthenia gravis (gMG) — that people with the chronic autoimmune condition can use at home. These approvals, by the Pharmaceuticals and Medical Devices Agency, or PMDA, will allow gMG…

Vyvgart Hytrulo formulation available for generalized MG in US

The recently approved prefilled syringe formulation of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that offers the possibility of self-administration is now available in the U.S. for eligible adults with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChRs). These ready-to-use syringes are intended to be…

Enrollment complete in Phase 2 trial testing DNTH103 for gMG

Enrollment is now complete for a Phase 2 clinical trial testing Dianthus Therapeutics‘ treatment candidate DNTH103 in people with generalized myasthenia gravis (gMG). According to the developer, the initial results from the global study, dubbed MAGIC (NCT06282159), are expected by early fall. MAGIC was launched early…

FDA approves J&J’s nipocalimab, now Imaavy, to treat gMG

The U.S. Food and Drug Administration (FDA) has approved nipocalimab as a treatment for adults and adolescents, ages 12 and older, with generalized myasthenia gravis (gMG) who have antibodies against the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) proteins. The newly approved therapy will be sold by developer…